This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Bevacizumab zirconium Zr-89
- DrugBank Accession Number
- DB14907
- Background
Bevacizumab zirconium Zr-89 is under investigation in clinical trial NCT01338090 (89Zr-bevacizumab PET Imaging in Patients With Neuroendocrine Tumors).
- Type
- Biotech
- Groups
- Investigational
- Synonyms
- 89ZR-BEVACIZUMAB
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Bevacizumab zirconium Zr-89. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Bevacizumab zirconium Zr-89. Aducanumab The risk or severity of adverse effects can be increased when Aducanumab is combined with Bevacizumab zirconium Zr-89. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bevacizumab zirconium Zr-89. Alirocumab The risk or severity of adverse effects can be increased when Alirocumab is combined with Bevacizumab zirconium Zr-89. - Food Interactions
- Not Available
Categories
- Drug Categories
- Amino Acids, Peptides, and Proteins
- Antibodies
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Blood Proteins
- Compounds used in a research, industrial, or household setting
- Diagnostic Uses of Chemicals
- Elements
- Globulins
- Immunoglobulins
- Immunoproteins
- Indicators and Reagents
- Isotopes
- Laboratory Chemicals
- Metals
- Metals, Heavy
- Proteins
- Radiopharmaceuticals
- Serum Globulins
- Transition Elements
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- B552L536ZL
- CAS number
- Not Available
References
- General References
- Not Available
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 0 Completed Diagnostic Inflammatory Breast Carcinoma 1 Not Available Completed Not Available Neuroendocrine Tumors 1 Not Available Recruiting Not Available Neurofibromatosis, type 2 (acoustic neurofibromatosis) 1 Not Available Unknown Status Diagnostic Multiple Myeloma (MM) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at May 20, 2019 14:33 / Updated at June 12, 2020 16:53